RhumbLine Advisers
SGP icon

RhumbLine Advisers’s SpyGlass Pharma SGP Stock Holding History

RhumbLine Advisers’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$318K Buy
12,225
+381
+3% +$9.39K ﹤0.01% 3006
2026
Q2 		$264K Buy
+11,844
New +$257K ﹤0.01% 3145

Other funds holding SGP

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Police & Firemen's Retirement System of New Jersey
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13B AUM 35.88% 1-Year Est. Return

RhumbLine Advisers's SGP Position: Q3 2026 in Review

RhumbLine Advisers increased its SpyGlass Pharma (SGP) stake by 3.2% in Q3 2026, buying an estimated $9.39K and bringing the position to 12,225 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #3006.

RhumbLine Advisers first reported a position in SGP in Q2 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold SGP as of Q3 2026.

  • RhumbLine Advisers held 12,225 shares of SpyGlass Pharma worth $318K as of Q3 2026.
  • RhumbLine Advisers bought 381 SpyGlass Pharma shares in Q3 2026, an estimated $9.39K.
  • SpyGlass Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3006 holding.
  • RhumbLine Advisers first reported a position in SpyGlass Pharma in Q2 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.